PolyMedix has completed two Phase 1 clinical trials in which a combined total of 77 healthy subjects received PMX-30063. In those clinical trials, PMX-30063 was safely administered in single or multiple doses without serious adverse effects. The only drug-related reactions of clinical importance to date have been paresthesias (abnormal sensations of numbness and tingling), which were mild, transient, non-disabling, and resolved on their own.
Btw, I don't like to even guess at valuations since too many variables exist.
Message in reply to:
Do we know the total headcount of patients that had taken Bril altogether? That's just safety profile of drug as to why they'll be testing Bril Phase II patients in CV19 patients?
Bril could be worth as much as a 10b tag price since its the flagship. Cv19 trials will help us get to $3b+ valuation. Maybe $5b cash upfront plus up to $5b in CVR? Ipix can throw in K for free!
To follow KarinCA, click here then click "Follow This Member" under my photo.
Be kinder than necessary, for everyone you meet is fighting some kind of battle.